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ABSTRACT 
Acetylsalicylic acid (ASA) or aspirin is a pro-dmg of salicylates which has signiﬁcant 
effect in reducing the cardiovascular events. Potential polymorphic enzymes 
responsible for the pharmacokinetic variations of ASA include cyclooxygenase-l 
(COX-ll UDP—glucuronosyltransferase (UGT1A6) and P450 (CYP) (CYP2C9). The 
main objective of this study is to determine the types and frequencies of variants of 
genes encoding COX-1 04-8420), UGT1A6 (UGT1A6*2; A5416 and UGTIA6*3; 
A5220 and CYP2C9 (CYP2C9*3; A1075C) in the three major ethnic groups in 
Malaysian population (Malays, Chinese and Indian), The relevance of those 
polymorphisms in patients with cardiovascular disease was investigated, The project 
was approved by relevant Research Ethics Committee, A total of 165 patients with 
cardiovascular disease who were treated with 75-150 mg daily dose of aspirin and 300 
healthy volunteer participants were rccmitcd‘ DNA was cxtrac‘ed from the blood 
samples and genotyped for the single nucleotide polymorphisms (SNPs) using allele 
speciﬁc polymerase chain reaction (AS-PCR). All statistical analysis was performed 
using SPSS software version 240. p—values S 0.05 were considered statistically 
signiﬁcant, The association between genotype and adverse effect of aspin'n therapy 
was estimated using odd ratio (OR) For UGTIA6, the pair-wise of both SNPS linkage 
disequilibrium (LD) was computed using Haplovicw. The variants frequencies for 
UGT]A6*2,*3 and CYP2C9*3 were 22.83%, 30.0% and 650%, respectively; while 
COX-I (A-84ZG) was absent. We found that the genotype for both polymorphisms in 
UGTIA6 and CYP2C9“3 were signiﬁcantly different between Indians, Malays and 
Chinese ethnic. The level of bilirubin and triglyceride of patients with different 
genotypes of UGTIA6 and CYP2C9*3 were signiﬁcantly different (p-value < 0405), 
respectively. In addition, CYP2C9*3 was found associated with gastritis events with 
odd ratio (OR) 68 (95 “/0 Cl: L39 — 33.19; P : 0.033), SNPS ofA54lG and A522C 
among the Indians show swung linkage disequilibrium with D‘ value of 1.0. This 
study had identiﬁed signiﬁcant association of genetic polymorphisms of UGTIA6 and 
CYP2C9*3 with gastritis event, level of bilirubin and triglyceride, Screening of 
patients with dcfecrive genetic variants could be of relevance in the clinical setting in 
identifying patients at risk of aspirin induced adverse effecL However, a iiiandomized, 
clinical study of bigger sample size would be needed before it is translated m clinical 
routme. 
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CHAPTER ONE 
INTRODUCTION 
1.1 INTRODUCTION 
Acetylsalicylic acid (ASA) or aspirin is a pro-drug of various forms of 
salicylates which has anti-inﬂammamry activities (Wu, 2000), This non-steroidal anti- 
inﬂamma‘ory drug (NSAIDS) is ‘hc most commonly used antiplatelet in prevention or 
‘reatment of cardiovascular disease, also as an over—the-counler medication for the 
treatment of pain and inﬂammation. It has been shown that aspirin therapy reduced the 
risk of vascular death and the risk of non—fatal myocardial infarction and stroke 
(Hennckcns ct 211., I997). 
Aspirin (75-150 mg, daily) has been found to reduce risk of vascular events by 
approximately 32% in patients with cardiovascular disease (CVD) (Baigent et 3],, 
2002) However, a substantial number of people still suffer from cardiovascular 
events, although they were already on aspirin treatment (Eikclboom el (11., 2002). For 
instance in Malaysia. although aspirin are available, CVD is su'll the foremost cause of 
monality. This phenomenon may be due to inter—individual variability in 
pharmacokinetic (PK) or phannacodynamic (PD) resulting in different drug responses 
(Agl’mdez at al., 2009)‘ Genetic variations have been shown to inﬂuence the efﬁcacy 
of various drugs including aspirinl Those polymorphic enzymes potentially affecting 
PK-PD of aspirin include cyclnoxygenase—l (COX-1), UDP-glucuronosyllransferase 
1A6 (UGTlAé) and P450 (CYP2C9) enzyme. 
COX-1 is an enzyme that is directly and irreversibly inhibited by aspirin which 
consequemly decrease the formation of precursors of prostaglandins and 
Ihromboxanes, Genetic variants in COX-l gene were suggested to modulate 
arachidonic acid-induced platelet aggregation and serum Ihromboxane B2 (TXBZ) 
levels in patients trcmed with aspirin, Moreover, the polymorphic UDP- 
glucuronosyltransferasc (UGT1A6) and P450 CYP2C9 enzyme is reported to be 
associated with altered enzyme function which affect aspirin metabolism and efﬁcacy. 
All these polymorphic enzymes could modulate the therapcuﬁc effect of aspirin in 
treating or preventing CVD. These polymorphic enzymes are believed to cause 
increase risk of adverse effect. It is tempting to reason that; the carriers of variant
